| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
Duloxetine HCl (formerly LY-248686 HCl; LY248686; trade names Cymbalta; Yentreve), the hydrochloride salt of Duloxetine which is an approved antidepressant medication, is a potent serotonin-norepinephrine reuptake inhibitor (SNRI) with potential anti-depressive activity. It inhibits SNRI with a Ki of 4.6 nM. Duloxetine has been employed in the treatment of a number of indications, including stress urinary incontinence, fibromyalgia, neuropathic pain, and major depressive disorders. (GAD). One of the brand names for duloxetine that is marketed is Cymbalta.
| Targets |
5-HT
|
|---|---|
| ln Vitro |
Duloxetine ((S)-Duloxetine hydrochloride) (sold under the brand names Cymbalta, Ariclaim, Xeristar, Yentreve, Duzela, Dulane) is an SNRI (serotonin-norepinephrine reuptake inhibitor) that Eli Lilly makes and sells. It is recommended for both generalized anxiety disorder (GAD) and major depressive disorder. Moreover, duloxetine is approved for the treatment of musculoskeletal pain and osteoarthritis. Due to worries about liver toxicity and suicidal thoughts, duloxetine was not approved for this indication in the US; however, it was approved in Europe, where it is advised as a supplement to surgery in cases of stress urinary incontinence. It can also relieve the symptoms of painful peripheral neuropathy, particularly diabetic neuropathy, and it is used to control the symptoms of fibromyalgia. Duloxetine is mostly used to treat major depressive disorder, general anxiety disorder, stress-related urinary incontinence, painful peripheral neuropathy, fibromyalgia, chronic lower back pain, and musculoskeletal pain linked to osteoarthritis. Numerous other indications are being researched on it[1][2].
|
| References |
|
| Molecular Formula |
C18H20CLNOS
|
|
|---|---|---|
| Molecular Weight |
333.88
|
|
| Exact Mass |
333.1
|
|
| Elemental Analysis |
C, 64.75; H, 6.04; Cl, 10.62; N, 4.20; O, 4.79; S, 9.60
|
|
| CAS # |
136434-34-9
|
|
| Related CAS # |
Duloxetine; 116539-59-4; Duloxetine-d3 hydrochloride; 1435727-97-1; (±)-Duloxetine hydrochloride; 947316-47-4; Duloxetine metabolite Para-Naphthol Duloxetine; 949095-98-1
|
|
| Appearance |
Solid powder
|
|
| SMILES |
CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32.Cl
|
|
| InChi Key |
BFFSMCNJSOPUAY-LMOVPXPDSA-N
|
|
| InChi Code |
InChI=1S/C18H19NOS.ClH/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16;/h2-10,13,17,19H,11-12H2,1H3;1H/t17-;/m0./s1
|
|
| Chemical Name |
(3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine;hydrochloride
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9951 mL | 14.9754 mL | 29.9509 mL | |
| 5 mM | 0.5990 mL | 2.9951 mL | 5.9902 mL | |
| 10 mM | 0.2995 mL | 1.4975 mL | 2.9951 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05267873 | Active Recruiting |
Drug: Duloxetine, Vortioxetine | Depressive Disorder, Major | Johns Hopkins Bloomberg School of Public Health |
January 1, 2015 | N/A |
| NCT05930912 | Active Recruiting |
Drug: sertraline 50mg Drug: Duloxetine 20 MG |
PTSD OCD |
Yang I. Pachankis, PhD | June 1, 2023 | N/A |
| NCT05550506 | Recruiting | Drug: Duloxetine | Chronic Pain Fibromyalgia |
Cukurova University | July 27, 2022 | N/A |
| NCT05611749 | Not yet recruiting | Drug: Duloxetine 60 MG Other: Placebo |
Narcotic Use Opioid Use |
Scripps Health | November 15, 2022 | Phase 2 |
| NCT05311774 | Not yet recruiting | Drug: Duloxetine 30 mg Drug: Tramadol |
Cancer Pain | Assiut University | April 2022 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA